Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Curcumin-loaded nanocomplexes ameliorate the severity of nonalcoholic steatohepatitis in hamsters infected with Opisthorchis viverrini.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
- Publication Information:
Original Publication: San Francisco, CA : Public Library of Science
- Subject Terms:
- Abstract:
Background: Comorbidity of Opisthorchis viverrini (OV) infection and nonalcoholic fatty-liver disease (NAFLD) enhances NAFLD progression to nonalcoholic steatohepatitis (NASH) by promoting severe liver inflammation and fibrosis. Here, we investigated the effect of supplementation with curcumin-loaded nanocomplexes (CNCs) on the severity of NASH in hamsters.
Methodology: Hamsters were placed in experimental groups as follows: fed standard chow diet (normal control, NC); fed only high-fat and high-fructose (HFF) diet; O. viverrini-infected and fed HFF diet (HFFOV); group fed with blank nanocomplexes (HFFOV+BNCs); groups fed different doses of CNCs (25, 50 and 100 mg/kg body weight: HFFOV+CNCs25; HFFOV+CNCs50; HFFOV+CNCs100, respectively) and a group given native curcumin (HFFOV+CUR). All treatment were for three months.
Results: The HFF group revealed NAFLD as evidenced by hepatic fat accumulation, ballooning, mild inflammation and little or no fibrosis. These changes were more obvious in the HFFOV group, indicating development of NASH. In contrast, in the HFFOV+CNCs50 group, histopathological features indicated that hepatic fat accumulation, cell ballooning, cell inflammation and fibrosis were lower than in other treatment groups. Relevantly, the expression of lipid-uptake genes, including fatty-acid uptake (cluster of differentiation 36), was reduced, which was associated with the lowering of alanine aminotransferase, total cholesterol and triglyceride (TG) levels. Reduced expression of an inflammation marker (high-mobility group box protein 1) and a fibrosis marker (alpha smooth-muscle actin) were also observed in the HFFOV+CNCs50 group.
Conclusion: CNCs treatment attenuates the severity of NASH by decreasing hepatic steatosis, inflammation, and fibrosis as well as TG synthesis. CNCs mitigate the severity of NASH in this preclinical study, which indicates promise for future use in patients.
Competing Interests: The authors have declared that no competing interests exist.
- References:
Front Endocrinol (Lausanne). 2020 Dec 14;11:597648. (PMID: 33384662)
Toxicol Pathol. 2010 Dec;38(7 Suppl):5S-81S. (PMID: 21191096)
Avicenna J Phytomed. 2016 Sep-Oct;6(5):567-577. (PMID: 27761427)
J Lipid Res. 2016 Jul;57(7):1243-55. (PMID: 27220352)
Nutrients. 2019 Oct 21;11(10):. (PMID: 31640183)
Physiol Rep. 2018 Jul;6(14):e13789. (PMID: 30009570)
J Gastroenterol. 2013 Apr;48(4):434-41. (PMID: 23397118)
Toxicol Appl Pharmacol. 2016 Aug 1;304:99-109. (PMID: 27208389)
Parasitol Int. 2012 Mar;61(1):208-11. (PMID: 21771664)
Int Immunopharmacol. 2017 Mar;44:174-182. (PMID: 28110063)
Gut Liver. 2012 Apr;6(2):149-71. (PMID: 22570745)
AAPS J. 2006 Jul 07;8(3):E443-9. (PMID: 17025261)
Acta Trop. 2009 Aug;111(2):181-91. (PMID: 19427296)
Nutrients. 2018 Oct 19;10(10):. (PMID: 30347782)
Biomed Res Int. 2017;2017:8234507. (PMID: 28770225)
Environ Sci Pollut Res Int. 2020 Jul;27(20):25271-25277. (PMID: 32347481)
Mol Metab. 2021 Aug;50:101111. (PMID: 33160101)
Int J Mol Sci. 2021 Feb 26;22(5):. (PMID: 33652942)
J Adv Res. 2021 Jun 08;34:109-122. (PMID: 35024184)
Am J Trop Med Hyg. 2008 Apr;78(4):564-73. (PMID: 18385350)
Infect Dis Poverty. 2019 Mar 20;8(1):18. (PMID: 30890188)
Ann Hepatol. 2018 Aug 24;17(5):802-809. (PMID: 30145559)
Trends Parasitol. 2012 Oct;28(10):395-407. (PMID: 22947297)
Plant Foods Hum Nutr. 2017 Mar;72(1):1-12. (PMID: 27995378)
Front Endocrinol (Lausanne). 2020 Nov 26;11:597583. (PMID: 33324348)
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. (PMID: 28930295)
Korean J Parasitol. 2013 Dec;51(6):703-10. (PMID: 24516277)
Am J Trop Med Hyg. 2019 Nov;101(5):1161-1169. (PMID: 31482785)
Toxicol Rep. 2021 Jun 30;8:1346-1357. (PMID: 34277359)
J Biomed Res. 2013 Jan;27(1):1-13. (PMID: 23554788)
Front Pharmacol. 2020 May 12;11:601. (PMID: 32477116)
Nutr Metab (Lond). 2019 Jan 28;16:8. (PMID: 30705687)
Cell Metab. 2010 May 5;11(5):402-11. (PMID: 20444420)
Nutrients. 2019 Nov 08;11(11):. (PMID: 31717261)
Nanomedicine. 2016 Jan;12(1):21-32. (PMID: 26542278)
Nat Rev Dis Primers. 2015 Dec 17;1:15080. (PMID: 27188459)
J Hepatol. 2016 Sep;65(3):579-88. (PMID: 27261415)
BMC Cancer. 2015 Jun 09;15:459. (PMID: 26054405)
Evid Based Complement Alternat Med. 2020 Jul 17;2020:2892917. (PMID: 32724322)
Ann Hepatol. 2017 Oct 16;16(6):835-841. (PMID: 29055920)
Hepatology. 2012 Nov;56(5):1751-9. (PMID: 22707395)
Front Med (Lausanne). 2021 Jun 30;8:691696. (PMID: 34277666)
BMJ Open. 2017 Jul 10;7(7):e016914. (PMID: 28698350)
Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752. (PMID: 32413340)
Annu Rev Nutr. 2014;34:281-303. (PMID: 24850384)
Front Oncol. 2020 Sep 08;10:1788. (PMID: 33014877)
- Accession Number:
0 (Actins)
0 (Lipids)
0 (Triglycerides)
30237-26-4 (Fructose)
97C5T2UQ7J (Cholesterol)
EC 2.6.1.2 (Alanine Transaminase)
IT942ZTH98 (Curcumin)
- Publication Date:
Date Created: 20220927 Date Completed: 20220929 Latest Revision: 20221007
- Publication Date:
20240829
- Accession Number:
PMC9514634
- Accession Number:
10.1371/journal.pone.0275273
- Accession Number:
36166461
No Comments.